SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	(18) SUBSEQUENT EVENTS On July 1, 2024, the Company entered into an exclusive license agreement with TwinStrand Biosciences, Inc. (“TwinStrand”), under which the Company will have the ability to use, commercialize, and sublicense the acquired intellectual property related to the cell free nucleic acid sequencing technology. Under the license agreement, the Company made upfront payments to TwinStrand totaling $45.0 million in July 2024. The license will be accounted for as an asset acquisition and the upfront consideration, which will be classified as an intangible asset in the condensed consolidated balance sheet, will be amortized through amortization of acquired intangible assets in the condensed consolidated statement of operations over its estimated useful life.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration